Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin)

Simple item page
dc.contributor.authorGupta, A.
dc.contributor.authorMuecke, J.
dc.date.issued2008
dc.description.abstractPURPOSE: To evaluate the safety and efficacy of intravitreal injection of bevacizumab as a treatment option for radiation maculopathy secondary to plaque radiotherapy. METHODS: Interventional case series of five patients who developed radiation maculopathy complicating plaque radiotherapy with ruthenium 106 for choroidal melanoma. One to two intravitreal injections of bevacizumab (0.5 mL) were given, with an interval of 4 weeks between each injection. The main outcome measures were visual acuity and results of clinical ophthalmic examination and optical coherence tomography. RESULTS: Preinjection visual acuity ranged from hand movements to 20/25. The average preinjection central macular thickness measured by optical coherence tomography was 351 microm. Three of five patients had no improvement in macular edema after treatment with a single injection of bevacizumab at the 2-week follow-up (average postinjection central macular thickness, 287 microm). Maculopathy in these three patients was long-standing (3-5 years). Improvement in visual acuity occurred in two patients (from 20/30 to 20/25 and from 20/25 to 20/20). Maculopathy in these two patients was diagnosed 1 week before treatment was offered. Resolution of macular edema occurred after a single injection in Patient 4 and after two injections in Patient 5. Patient 4 did not receive direct radiation to the fovea. All but one patient (Patient 5; dose, 8,000 cGy) received a radiation dose of 10,000 cGy to the tumor apex. CONCLUSIONS: In this series, treatment of radiation maculopathy with intravitreal injection of bevacizumab was useful in two patients as measured by improvement in visual acuity due to resolution of macular edema. These patients were younger and had macular edema for a shorter duration. One patient did not receive direct radiation to the fovea, and the other had a lower dose of radiation
dc.description.statementofresponsibilityGupta A and Muecke J.S.
dc.identifier.citationRetina: the Journal of Retinal and Vitreous Diseases, 2008; 28(7):964-968
dc.identifier.doi10.1097/IAE.0b013e3181706302
dc.identifier.issn0275-004X
dc.identifier.issn1539-2864
dc.identifier.urihttp://hdl.handle.net/2440/55377
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.source.urihttps://doi.org/10.1097/iae.0b013e3181706302
dc.subjectMacula Lutea
dc.subjectVitreous Body
dc.subjectHumans
dc.subjectMelanoma
dc.subjectChoroid Neoplasms
dc.subjectRetinal Diseases
dc.subjectRadiation Injuries
dc.subjectRuthenium Radioisotopes
dc.subjectAngiogenesis Inhibitors
dc.subjectVascular Endothelial Growth Factor A
dc.subjectAntibodies, Monoclonal
dc.subjectTomography, Optical Coherence
dc.subjectBrachytherapy
dc.subjectRetreatment
dc.subjectInjections
dc.subjectRetrospective Studies
dc.subjectFollow-Up Studies
dc.subjectVisual Acuity
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectBevacizumab
dc.titleTreatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin)
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Opthalmology & Visual Sciences publications